Disease-oriented evidence |
Preclinical studies in castration-resistant prostate cancer cell lines and mouse xenograft models, including preclinical models harboring androgen receptor amplification. |
Enzalutamide mediates its activity by potently antagonizing the androgen receptor, inhibits nuclear translocation of the androgen receptor, and impairs binding of the androgen receptor to promoter areas of androgen-regulated genes. |
Patient-oriented evidence |
Phase I/II clinical trial in men with chemotherapy-naïve and chemotherapy-pretreated metastatic castration-resistant prostate cancer (NCT00510718). Phase III randomized-controlled trial in men with chemotherapy-pretreated metastatic castration-resistant prostate cancer (NCT00974311). |
Enzalutamide improved overall survival compared to placebo. Enzalutamide was also superior to placebo with respect to all secondary clinical endpoints, as well as quality-of-life endpoints. The safety profile of enzalutamide is favorable and common adverse events include fatigue, headache, and hot flashes; 1% of patients experienced seizure. Enzalutamide was approved by the US Food and Drug Administration on August 31, 2012 for men with docetaxel-pretreated metastatic castration-resistant prostate cancer. |
Economic evidence |
Pharmacoeconomic studies have not yet been conducted. |
The current market price for enzalutamide is approximately $7000 per month. |